The onset time of anagrelide for essential thrombocythemia varies among individuals and is not consistent. Clinical trials have shown that the median onset time is 7 days.
Anagrelide is an oral antiplatelet agent that demonstrates significant efficacy in the treatment of thrombocytosis caused by various etiologies, including essential thrombocythemia, and helps alleviate disease progression.
Onset time may be influenced by individual differences, disease stage, physical condition, and drug tolerance. Therefore, use under the guidance of a physician is necessary.
